Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients

(2013) B. D. Curti et al.   CANCER RESEARCH

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

(2013) Yannick Bulliard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Antibodies Targeting Human OX40 Expand Effector T Cells and Block Inducible and Natural Regulatory T Cell Function

(2013) K. S. Voo et al.   JOURNAL OF IMMUNOLOGY

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor Growth

(2012) C. Claus et al.   CANCER RESEARCH

Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies

(2012) I. Verbrugge et al.   CANCER RESEARCH

Modulation of GITR for cancer immunotherapy

(2012) David A Schaer et al.   CURRENT OPINION IN IMMUNOLOGY

CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression

(2012) Christian Schürch et al.   JOURNAL OF CLINICAL INVESTIGATION

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

(2012) Holbrook E. Kohrt et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunotherapy of Cancer with 4-1BB

(2012) D. S. Vinay et al.   MOLECULAR CANCER THERAPEUTICS

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

(2012) Hirokazu Matsushita et al.   NATURE

Expression of tumour-specific antigens underlies cancer immunoediting

(2012) Michel DuPage et al.   NATURE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual Anti-OX40/IL-2 Therapy Augments Tumor Immunotherapy via IL-2R-Mediated Regulation of OX40 Expression

(2012) William L. Redmond et al.   PLoS One

CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo

(2011) D.-G. Song et al.   BLOOD

Pharmacological modulation of GITRL/GITR system: therapeutic perspectives

(2011) Giuseppe Nocentini et al.   BRITISH JOURNAL OF PHARMACOLOGY

Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory

(2011) Jang-June Park et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis

(2011) Kendra Garrison et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1

(2011) J. Fourcade et al.   CANCER RESEARCH

4-1BB signaling beyond T cells

(2011) Dass S Vinay et al.   Cellular & Molecular Immunology

Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells

(2011) Scott K. Pruitt et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Science gone translational: the OX40 agonist story

(2011) Andrew D. Weinberg et al.   IMMUNOLOGICAL REVIEWS

Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells

(2011) Mercedes B. Fuertes et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Costimulation Through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-infiltrating Lymphocytes From Activation-induced Cell Death and Enhances Antitumor Effector Function

(2011) Jessica Ann Hernandez-Chacon et al.   JOURNAL OF IMMUNOTHERAPY

Combinatorial Therapy for Liver Metastatic Colon Cancer: Dendritic Cell Vaccine and Low-Dose Agonistic Anti-4-1BB Antibody Co-Stimulatory Signal

(2011) Hyunah Lee et al.   JOURNAL OF SURGICAL RESEARCH

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production

(2011) Michael A. Curran et al.   PLoS One

Detection of Intra-Tumor Self Antigen Recognition during Melanoma Tumor Progression in Mice Using Advanced Multimode Confocal/Two Photon Microscope

(2011) David A. Schaer et al.   PLoS One

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

(2011) J. Yuan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Control of Immunity by the TNFR-Related Molecule OX40 (CD134)

(2010) Michael Croft   Annual Review of Immunology

A Therapeutic OX40 Agonist Dynamically Alters Dendritic, Endothelial, and T Cell Subsets within the Established Tumor Microenvironment

(2010) A. D. Pardee et al.   CANCER RESEARCH

Acquired TNFRSF14 Mutations in Follicular Lymphoma Are Associated with Worse Prognosis

(2010) K.-J. J. Cheung et al.   CANCER RESEARCH

Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals

(2010) J. Mitsui et al.   CLINICAL CANCER RESEARCH

A non-redundant role for OX40 in the competitive fitness of Treg in response to IL-2

(2010) Silvia Piconese et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy

(2010) Juan Dubrot et al.   INTERNATIONAL JOURNAL OF CANCER

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

(2010) Laurent Derré et al.   JOURNAL OF CLINICAL INVESTIGATION

OX40 is required for regulatory T cell–mediated control of colitis

(2010) Thibault Griseri et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules

(2010) K. Takeda et al.   JOURNAL OF IMMUNOLOGY

Combining T-cell Vaccination and Application of Agonistic Anti-GITR mAb (DTA-1) Induces Complete Eradication of HPV Oncogene Expressing Tumors in Mice

(2010) Corinna Hoffmann et al.   JOURNAL OF IMMUNOTHERAPY

Adjuvant Therapy With Agonistic Antibodies to CD134 (OX40) Increases Local Control After Surgical or Radiation Therapy of Cancer in Mice

(2010) Michael J. Gough et al.   JOURNAL OF IMMUNOTHERAPY

Role of CD27/CD70 pathway of activation in immunity and tolerance

(2010) Julie Denoeud et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluating the Cellular Targets of Anti-4-1BB Agonist Antibody during Immunotherapy of a Pre-Established Tumor in Mice

(2010) Gloria H. Y. Lin et al.   PLoS One

Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation

(2010) Adam D. Cohen et al.   PLoS One

Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies

(2010) Paolo A. Ascierto et al.   SEMINARS IN ONCOLOGY

Signaling Through OX40 Enhances Antitumor Immunity

(2010) Shawn M. Jensen et al.   SEMINARS IN ONCOLOGY

Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy

(2009) D Boczkowski et al.   CANCER GENE THERAPY

Glucocorticoid-induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigen-specific CD8+T cells with tumor regression

(2009) Naoko Imai et al.   CANCER SCIENCE

The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation

(2009) Guifang Cai et al.   IMMUNOLOGICAL REVIEWS

Combination of Adoptive Cell Transfer and Antibody Injection Can Eradicate Established Tumors in Mice–Anin vivostudy using anti-OX40mAb, anti-CD25mAb and anti-CTLA4mAb–

(2009) Akira Watanabe et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

CD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production

(2009) Victor Peperzak et al.   JOURNAL OF CLINICAL INVESTIGATION

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis

(2009) Daniel Hirschhorn-Cymerman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cutting Edge: OX40 Agonists Can Drive Regulatory T Cell Expansion if the Cytokine Milieu Is Right

(2009) C. E. Ruby et al.   JOURNAL OF IMMUNOLOGY

T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy

(2008) R. Houot et al.   BLOOD

Regulatory T Cell-Resistant CD8+ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling

(2008) H. Nishikawa et al.   CANCER RESEARCH

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH

Enhancement of T-cell-mediated anti-tumour immunity via the ectopically expressed glucocorticoid-induced tumour necrosis factor receptor-related receptor ligand (GITRL) on tumours

(2008) Jinhua Piao et al.   IMMUNOLOGY

Structural basis for ligand-mediated mouse GITR activation

(2008) Z. Zhou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Evolution of GITRL immune function: Murine GITRL exhibits unique structural and biochemical properties within the TNF superfamily

(2008) K. Chattopadhyay et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA